Bentley Pharma (BNT) Announces Adjustment To Teva (TEVA) Merger Price
Bentley Pharmaceuticals, Inc. (NYSE: BNT) said the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX).
Bentley stockholders will receive from Teva a final per-share purchase price of approximately $14.82 in cash in exchange for their Bentley common stock if the merger agreement is approved by Bentley’s stockholders and the other closing conditions are satisfied or waived in accordance with the merger agreement.
Bentley stockholders will receive from Teva a final per-share purchase price of approximately $14.82 in cash in exchange for their Bentley common stock if the merger agreement is approved by Bentley’s stockholders and the other closing conditions are satisfied or waived in accordance with the merger agreement.
You May Also Be Interested In
- UPDATE: SAP's (SAP) America Unit to Buy Ariba (ARBA) for $45/Share
- Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
- UPDATE: RR Donnelley (RRD) to Buy Edgar Online (EDGR) for $70.5M
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
